Mesa Laboratories Acquires Gyros Protein Technologies

Mesa Laboratories Acquires Agena Bioscience

September 14, 2021

Medical Devices

Mesa Laboratories, Inc. (NASDAQ:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. for $300 million in cash. Agena, a San Diego–based molecular diagnostics and genomics tools company, is expected to add roughly $63–67 million of revenue (about 65% recurring) in the first 12 months and will form Mesa’s new Clinical Genomics Division.

Grain & Protein Technologies Acquires Munters FoodTech Equipment

June 3, 2025

Manufacturing

Grain & Protein Technologies (GPT) has completed the acquisition of Munters FoodTech Equipment, the business that sells and services the Aerotech, Euroemme, and Reventa branded products. The deal brings approximately 400 Munters FoodTech Equipment employees into GPT and expands GPT's product portfolio and capabilities in climate control and air treatment for the protein and agribusiness segments.

Arcline Investment Management Acquires Polypeptide Therapeutic Solutions (PTS)

April 27, 2021

Biotechnology

Arcline Investment Management, a growth-oriented private equity firm, has acquired Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners. PTS is a Valencia-based GMP CDMO specializing in polyamino-acid (PAA) nanoparticle encapsulation and related drug-delivery services; Arcline plans to scale GMP production and expand the company's technology portfolio to support mRNA, gene/cell therapies, biologics and vaccines.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

Novartis Acquires Gyroscope Therapeutics

December 22, 2021

Biotechnology

Novartis has agreed to acquire UK-based Gyroscope Therapeutics for $800 million upfront with up to $700 million in contingent milestone payments, adding GT005 — an AAV2-based, one-time investigational gene therapy for geographic atrophy secondary to AMD — and early-stage retinal assets to its ophthalmology pipeline. The transaction is subject to customary closing conditions and regulatory approvals; Gyroscope will continue to operate independently until closing.

MLM Medical Labs Acquires MD Biosciences, Inc.

October 27, 2020

Healthcare Services

MLM Medical Labs, a Great Point Partners portfolio company, has acquired MD Biosciences, Inc., an Oakdale, Minnesota-based provider of preclinical, translational and clinical-phase contract research services. The deal expands MLM's U.S. footprint and adds immunohistochemistry, preclinical research and histopathology capabilities to its global laboratory platform as part of an integration with recent U.S. additions such as CirQuest Labs.